EUSA, GSK ink $44M pre-clinical antibody deal

EUSA Pharma will keep about half of the $44 million in up front fees and milestones it is scheduled to receive from GlaxoSmithKline for a license covering a pre-clinical antibody targeted at lymphoma and rheumatoid arthritis. The other half goes to its development partner, Vaccines Inc. The antibody--OP-R003--is a protein that targets interleukin-6, a common target for a number of drug developers.

"The out-licensing of this early-stage antibody is another strategic milestone for EUSA, as we continue to focus our business on marketed and late-stage products in the oncology, pain control and critical care areas," said Bryan Morton, CEO of EUSA, a developer based in the U.S. and the U.K.

- read the release for more info

Suggested Articles

Dewpoint Therapeutics aims to advance research in one of the more mysterious cell organelles: biomolecular condensates.

The FDA slapped a partial clinical hold on the phase 2/3 study of Inovio’s COVID-19 vaccine because it has “additional questions” about the trial.

Preclinical inflammatory disease biotech Ilias Biologics has grabbed a $20.6 million funding round as it eyes a 2021 human test of its leading asset.